Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00553631
Other study ID # HGT-GCB-039
Secondary ID 2007-002840-21
Status Completed
Phase Phase 3
First received
Last updated
Start date January 29, 2008
Est. completion date May 5, 2009

Study information

Verified date May 2021
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.


Description:

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the CNS. Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. GA-GCB (velaglucerase alfa) contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the efficacy and safety of GA-GCB (velaglucerase alfa) in comparison to imiglucerase in men, women, and children with Type 1 Gaucher disease.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date May 5, 2009
Est. primary completion date May 5, 2009
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria Includes: - The patient has a documented diagnosis and clinical manifestation of type 1 Gaucher disease - The patient is at least 2 years of age. - The patient has not received treatment for Gaucher disease (investigational products, miglustat, or imiglucerase) within 12 months prior to study entry, as documented in the patient's medical history. - Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy. - The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). - The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator. Exclusion Criteria Includes: - The patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease. - The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted. - The patient is known to be positive for human immunodeficiency virus (HIV). - The patient is known to be positive for hepatitis B and/or C. - The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study. - The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.). - The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
velaglucerase alfa
IV infusion, 60 U/kg every other week for 9 months
imiglucerase
IV infusion, 60 U/kg every other week for 9 months

Locations

Country Name City State
Argentina Your Health S.A. Buenos Aires
India Malabar Institute of Medical Sciences Ltd. Calicut Kerala
India All India Institute of Medical Sciences New Delhi
India KEM Hospital Research Centre Pune
Israel Shaare Zedek Medical Center Jerusalem
Paraguay Sociedad Espanola de Socorros Mutuos Asuncion
Russian Federation National Research Center for Haematology Moscow
Spain Hospital Universitario Miguel Servet Zaragoza
Tunisia La Rabta Hospital Tunis
United Kingdom The Royal Free Hospital London
United States Duke Children's Hospital & Health Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Shire

Countries where clinical trial is conducted

United States,  Argentina,  India,  Israel,  Paraguay,  Russian Federation,  Spain,  Tunisia,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. Baseline to Month 9
Secondary Change From Baseline to Month 9 in Platelet Counts for Each Treatment Group. Values shown are observed change from Baseline to Month 9. Baseline to Month 9
Secondary Change From Baseline to Month 9 in Normalized Liver Volume (Percent (%) Body Weight) for Each Treatment Group. Values shown are observed change from Baseline to Month 9. Measured by Magnetic resonance imaging (MRI). Liver volume has been normalized for percent (%) body weight for each treatment arm. Liver size relative to body weight = (Liver volume [cubic centimeter (cc)]/Body weight [kg]*1000. Baseline to Month 9
Secondary Change From Baseline to Month 9 in Normalized Spleen Volume (Percent (%) Body Weight) for Each Treatment Group. Values shown are observed change from Baseline to month 9. Measured by Magnetic resonance imaging (MRI). Spleen volume was normalized for percent (%) of body weight for each treatment arm. Spleen size relative to body weight=(Spleen volume [cc]/Body weight [kg])*100. Baseline to Month 9
Secondary Change From Baseline to Month 9 in Plasma Chitotriosidase for Each Treatment Group. Values shown are observed change from Baseline to Month 9. Units of measure is defined as nanomole per milliliter per hour. Baseline to Month 9.
Secondary Change From Baseline to Month 9 in Plasma Chemokine (C-C Motif) Ligand 18 (CCL18) for Each Treatment Group. Values shown are observed change from Baseline to Month 9. Baseline to Month 9
Secondary Number of Participants Who Developed Antibody for Each Treatment Group. Measure type is actual number of participants who developed antibodies to treatment; GA-GCB or imiglucerase. Antibody detection was based upon serum samples collected at various time points throughout the study. Serum samples were screened using an enzyme-linked immunosorbent assay (ELISA) and positive antibody confirmation was determined using a radioimmunoprecipitation assay (RIP); positive samples were also tested for enzyme neutralizing activity. Participant samples were compared to internal assay controls (positive/negative), positive samples were determined based upon individual assay criteria. Baseline to Month 9
Secondary Time to Response- Comparison of GA-GCB and Imiglucerase on the Earliest Time to Respond as Assessed Via Hemoglobin Concentration Time to response was defined as a = 1 g/dL improvement in hemoglobin levels relative to Baseline. Units (%) correlates to the percentage of participants who had a change of = 1 g/dL improvement in hemoglobin levels relative to Baseline during their participation in the study. Response rate at Month 9 compared to Baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00943111 - A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) Phase 3
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Active, not recruiting NCT00891202 - A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE) Phase 3
Recruiting NCT05253560 - Prodromal Parkinsonian Features in GBA1 Mutation Carriers
Completed NCT00813865 - A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients Phase 2
Completed NCT00433147 - A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy Phase 2
Completed NCT00635427 - An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease Phase 3
Completed NCT03950050 - Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy Phase 2
Terminated NCT03746587 - Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 Phase 2
Active, not recruiting NCT00358150 - A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients Phase 2
Completed NCT00446550 - A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease Phase 2
Recruiting NCT05447494 - Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease Phase 1/Phase 2
Completed NCT03333447 - Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
Completed NCT04120506 - Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) Phase 4
Completed NCT04353466 - Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs N/A
Completed NCT00430625 - A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease Phase 3
Withdrawn NCT00795197 - A Screening Study Evaluating Disease Status of Gaucher Type I Patients N/A
Completed NCT00364858 - Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease Phase 4
Recruiting NCT05487599 - A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) Phase 1/Phase 2
Recruiting NCT05324943 - A Gene Therapy Study in Patients With Gaucher Disease Type 1 Phase 1